Navigation Links
NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
Date:8/5/2009

SAN MATEO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date from August 16, 2009 to November 16, 2009 to review the new drug application (NDA) for Qutenza(TM) to manage pain associated with postherpetic neuralgia (PHN).

The extension resulted from the Company's recent submission of data requested by the agency late in the review cycle, which the FDA has classified as a major NDA amendment. Submission of a major amendment within three months of the PDUFA date can trigger a three-month extension to the original review timeline.

Anthony DiTonno, President and CEO, commented, "The FDA's three-month extension is not unexpected. We previously discussed the potential for this extension as a result of our responses to FDA requests for additional information. The information we submitted in July included the report from our recently completed C123 Study, which was performed at the request of the FDA. We believe that with this updated review timeline, if we gain approval in November, we may still achieve our overall goal of launching Qutenza in the United States in the first half of 2010."

Conference Call Details

The Company will hold its quarterly conference call to discuss this recent development as well as financial results for the second quarter of 2009, on August 7, 2009 at 9:00 a.m. ET (6:00 a.m. PT).

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at '/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
2. NeurogesX Added to Russell 3000 Index
3. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
4. NeurogesX to Present at Needham Life Sciences Conference
5. NeurogesX Receives European Commission Approval for Qutenza(TM)
6. NeurogesX Reports First Quarter 2009 Results
7. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
8. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
9. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
10. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
11. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...ov. 19 Omeros Corporatio...cial results for the third quarter ended September..., 2009, Omeros reported a net loss of $3.9 million... $7.4 million, or $2.54 per share, for the same pe...30, 2009, the Company reported a net loss of $15.5...
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 ...or in biotechnology for diabetes therapy, and a pr...ices to food, supplement, biotechnology and pharma...previously reported $6.3 million registered direct... shares of its common stock and warrants to purcha...
(Date:11/19/2009)...Md., Nov. 19 Spherix Inc...hnology for diabetes therapy, and a provider of te..., supplement, biotechnology and pharmaceutical com...nnual Meeting of Shareholders. ,, At the meetin...SPEX ) elected the following members to the Board ...
(Date:11/19/2009)...STER, Germany, November 19 MONITOR...ovember 16th, 2009 Flibanserin in the,indication t...arkinson,s,disease for orphan drug status designat...odopa-induced dyskinesia is a complication of the ...erious burden to some of those,affected, since it ...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...of your house always looking good, without cleanin...ssible with paint that can maintain itself and get... for producing photo-catalytic, self-cleaning coat...,s A*STAR (Agency for Science, Technology and Rese...patented process produces a coating containing the...
...rease 400% to $16 million in third quarter 2008; u...9 million non-cash goodwill impairment charge , ...-- Encorium Group, Inc. (Nasdaq: ENCO ) , a full...ion (CRO) conducting studies in over 30 countries ...d biotechnology companies, today announced its fin...
...EY CITY, New Jersey, November 26, Rosetta Genomics...e third quarter financial results on December 5, 2...s will host a conference call with a,simultaneous ...n Friday,December 5. , To access the live co...dial 1-866-966-5335; international participants ma...
Other Biology Technology:Photo-catalytic, self cleaning coating for building exteriors 2Photo-catalytic, self cleaning coating for building exteriors 3Photo-catalytic, self cleaning coating for building exteriors 4Encorium Reports Third Quarter 2008 Financial Results 2Encorium Reports Third Quarter 2008 Financial Results 3Encorium Reports Third Quarter 2008 Financial Results 4Encorium Reports Third Quarter 2008 Financial Results 5Encorium Reports Third Quarter 2008 Financial Results 6Encorium Reports Third Quarter 2008 Financial Results 7Encorium Reports Third Quarter 2008 Financial Results 8Encorium Reports Third Quarter 2008 Financial Results 9Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results 2
(Date:11/20/2009)... 2009) Scientists from the Marine Biogeochemistry...Research Laboratory (NRL) organized and led a team...tic expedition to initiate methane hydrate explora... variation of sediment contribution to Arctic clim...ter Polar Sea as a research platform, three cross-...
(Date:11/20/2009)...ber 19, 2009 The estimated 4.6 million Americans ...developing respiratory symptoms due to poor air qu... study undertaken earlier this year by investigato...nary Medicine. , The studywhich polled more than...rcent of individuals working in barns complained o...
(Date:11/20/2009)...single bacterial gene into yeast, researchers from... achieved three improvements in bioethanol product...l, less acetate and elimination of the major by-pr...hed in the scientific journal Applied and Environ...l is made by the yeast Saccharomyces cerevisiae fr...
Breaking Biology News(10 mins):International expedition investigates climate change, alternative fuels in Arctic 2Barn personnel experience higher-than-average rates of respiratory symptoms 2Delft breakthrough in bioethanol production from agricultural waste 2Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 56410 1Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 56410 2Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 56410 3Texas Kidney Community Expresses Hope DC Health Care Reform Debate Can Help Drive Continued Progress in Texas Opening Needed Dialysis Facilities 56408 1Texas Kidney Community Expresses Hope DC Health Care Reform Debate Can Help Drive Continued Progress in Texas Opening Needed Dialysis Facilities 56408 2Texas Kidney Community Expresses Hope DC Health Care Reform Debate Can Help Drive Continued Progress in Texas Opening Needed Dialysis Facilities 56408 3Mark G Ackermann Is Named New President and CEO of Lighthouse International 56406 1Mark G Ackermann Is Named New President and CEO of Lighthouse International 56406 2Mark G Ackermann Is Named New President and CEO of Lighthouse International 56406 3
...iotic that was banned for internal use in the Unit...lications, appears to block the genetic action of ...according to a study reported by San Francisco VA ...led by principal investigator Stephen M. Massa, MD...e August 16, 2005 issue of Proceedings of the Nati...
...n medicine is an ongoing challenge to blood servic...zfeldt-Jakob Disease (vCJD), emerge. An update on ... human form of Bovine Spongiform Encephalopathy (B... risk of transmission through blood transfusion wa...lood Transfusion Congress. At the "Safety in Trans...
...loped by the IST project OPTONANOGEN, a prototype ...ations of the BRCA1 gene that are responsible for ...ast cancer in women. The final system, however, co...y as well as proteins linked to viruses, chemical ... are a broad variety of applications for this syst...
Other Biology News:Old drug shows new promise for Huntington's Disease 2Old drug shows new promise for Huntington's Disease 3New results validating Pall prion reduction filter disclosed at ISBT Congress 2New results validating Pall prion reduction filter disclosed at ISBT Congress 3Nanotechnology to provide portable genetic risk detection 2
...a Western Protein Array was developed using a pate...n Protein Arrays are manufactured using high quali...e sources. A protein sample from each of 30 tissue...olecular weight marker on a large size SDS-PAGE ge...
...onfocal, the BD Pathway 415 is a cost effective al... can be field-upgraded to confocal if later applic...d autofocus is standard. You can elect to use the ...n of both. Robot-compatible, retractable plate tr...
a-Hyb Hybridization Station from Miltenyi Biotec
...rmal Fibroblasts (rabbit) and media. Cryo-preserve...at passage 25 (approx), supplied with kit (500 mL)... as a long-term culture, and is guaranteed to prov...om the date supplied, when used with the recommend...
Biology Products: